Ketamine and Magnesium for Refractory Neuropathic Pain A Randomized, Double-blind, Crossover Trial

被引:0
|
作者
Pickering, Gisele [1 ,2 ]
Pereira, Bruno [3 ]
Morel, Veronique [1 ]
Corriger, Alexandrine [1 ]
Giron, Fatiha [1 ]
Marcaillou, Fabienne [4 ]
Bidar-Beauvallot, Assiya [4 ]
Chandeze, Evelyne [4 ]
Lambert, Celine [3 ]
Bernard, Lise [5 ]
Delage, Noemie [4 ]
机构
[1] Univ Hosp Clermont Ferrand, Clin Pharmacol Dept, Inserm, CIC 1405, F-63000 Clermont Ferrand, France
[2] Clermont Auvergne Univ, Inserm 1107, F-63000 Clermont Ferrand, France
[3] Univ Hosp Clermont Ferrand, Clin Res & Innovat Dept, F-63000 Clermont Ferrand, France
[4] Univ Hosp Clermont Ferrand, Assessment & Treatment Pain Ctr, F-63000 Clermont Ferrand, France
[5] Univ Hosp Clermont Ferrand, Clin Res Temporary Authorizat Dept, F-63000 Clermont Ferrand, France
关键词
SF-36 HEALTH SURVEY; INTRAVENOUS KETAMINE; MORPHINE; SULFATE; QUESTIONNAIRE; METAANALYSIS; VALIDATION; MANAGEMENT; THERAPY;
D O I
10.1097/ALN.0000000000003327
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background: Ketamine is often used for the management of refractory chronic pain. There is, however, a paucity of trials exploring its analgesic effect several weeks after intravenous administration or in association with magnesium. The authors hypothesized that ketamine in neuropathic pain may provide pain relief and cognitive-emotional benefitversusplacebo and that a combination with magnesium may have an additive effect for 5 weeks. Methods: A randomized, double-blind, crossover, placebo-controlled study (NCT02467517) included 20 patients with neuropathic pain. Each ketamine-naive patient received one infusion every 35 days in a random order: ketamine (0.5 mg/kg)/placebo or ketamine (0.5 mg/kg)/magnesium sulfate (3g) or placebo/placebo. The primary endpoint was the area under the curve of daily pain intensity for a period of 35 days after infusion. Secondary endpoints included pain (at 7, 15, 21 and 28 days) and health-related, emotional, sleep, and quality of life questionnaires. Results: Daily pain intensity was not significantly different between the three groups (n = 20) over 35 days (mean area under the curve = 185 +/- 100, 196 +/- 92, and 187 +/- 90 pain score-days for ketamine, ketamine/magnesium, and placebo, respectively,P= 0.296). The effect size of the main endpoint was -0.2 (95% CI [-0.6 to 0.3];P= 0.425) for ketamineversusplacebo, 0.2 (95% CI [-0.3 to 0.6];P= 0.445) for placeboversusketamine/magnesium and -0.4 (95% CI [-0.8 to 0.1];P= 0.119) for ketamineversusketamine/magnesium. There were no significant differences in emotional, sleep, and quality of life measures. During placebo, ketamine, and ketamine/magnesium infusions, 10%, 20%, and 35% of patients respectively reported at least one adverse event. Conclusions: The results of this trial in neuropathic pain refuted the hypothesis that ketamine provided pain relief at 5 weeks and cognitive-emotional benefitversusplacebo and that a combination with magnesium had any additional analgesic effect.
引用
收藏
页码:154 / 164
页数:11
相关论文
共 50 条
  • [1] Botulinum toxin for diabetic neuropathic pain A randomized double-blind crossover trial
    Yuan, R. -Y.
    Sheu, J. -J.
    Yu, J. -M.
    Chen, W. -T.
    Tseng, I. -J.
    Chang, H. -H.
    Hu, C. -J.
    NEUROLOGY, 2009, 72 (17) : 1473 - 1478
  • [2] BOTULINUM TOXIN FOR DIABETIC NEUROPATHIC PAIN: A RANDOMIZED DOUBLE-BLIND CROSSOVER TRIAL BOTULINUM TOXIN FOR NEUROPATHIC PAIN?
    Torgovnick, Josh
    Arsura, Edward
    Sethi, Nitin K.
    NEUROLOGY, 2010, 74 (01) : 92 - 92
  • [3] A RANDOMIZED DOUBLE-BLIND CROSSOVER TRIAL OF INTRAVENOUS LIDOCAINE IN THE TREATMENT OF NEUROPATHIC CANCER PAIN
    BRUERA, E
    RIPAMONTI, C
    BRENNEIS, C
    MACMILLAN, K
    HANSON, J
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 1992, 7 (03) : 138 - 140
  • [4] Double-blind randomized trial of bupropion SR for the treatment of neuropathic pain
    Semenchuk, MR
    Sherman, SJ
    Davis, BE
    NEUROLOGY, 2001, 56 (08) : A204 - A204
  • [5] Melatonin for Neuropathic Pain: Protocol for a Double-blind, Randomized Controlled Trial
    Gilron, Ian
    Tu, Dongsheng
    Holden, Ronald R.
    Moulin, Dwight E.
    Duggan, Scott
    Milev, Roumen
    JMIR RESEARCH PROTOCOLS, 2022, 11 (09):
  • [6] Double-blind, randomized trial of bupropion SR for the treatment of neuropathic pain
    Semenchuk, MR
    Sherman, S
    Davis, B
    NEUROLOGY, 2001, 57 (09) : 1583 - 1588
  • [7] Investigating the role of neuropathic pain relief in decreasing gait variability in diabetes mellitus patients with neuropathic pain: a randomized, double-blind crossover trial
    Karmakar, Surshen
    Rashidian, Houman
    Chan, Cynthia
    Liu, CaiXia
    Toth, Cory
    JOURNAL OF NEUROENGINEERING AND REHABILITATION, 2014, 11
  • [8] Investigating the role of neuropathic pain relief in decreasing gait variability in diabetes mellitus patients with neuropathic pain: a randomized, double-blind crossover trial
    Surshen Karmakar
    Houman Rashidian
    Cynthia Chan
    CaiXia Liu
    Cory Toth
    Journal of NeuroEngineering and Rehabilitation, 11
  • [9] Topical 2% amitriptyline and 1% ketamine in neuropathic pain syndromes - A randomized, double-blind, placebo-controlled trial
    Lynch, ME
    Clark, AJ
    Sawynok, J
    Sullivan, MJL
    ANESTHESIOLOGY, 2005, 103 (01) : 140 - 146
  • [10] DEXTROMETHORPHAN FOR THE TREATMENT OF NEUROPATHIC PAIN - A DOUBLE-BLIND RANDOMIZED CONTROLLED CROSSOVER TRIAL WITH INTEGRAL N-OF-1 DESIGN
    MCQUAY, HJ
    CARROLL, D
    JADAD, AR
    GLYNN, CJ
    JACK, T
    MOORE, RA
    WIFFEN, PJ
    PAIN, 1994, 59 (01) : 127 - 133